vertex pharmaceuticals inc. Resources | BNET
On The Insider: Amy Winehouse Has Brain Damage?

BNET Industries

Vertex Pharmaceuticals Inc. (VRTX) is in the Pharma Industry

Revenue
Dec 31 2007
$199.0M
Profit
Dec 31 2007
($391.2M)
Market Cap
Sep 03 2008
$3.7B

Latest News and Analysis

Additional Resources

  • page 1 of 1
  • Incorporated: 1989
  • CEO: Dr. Joshua S. Boger Ph.D.
  • Employees: 1,132

Vertex Pharmaceuticals is engaged in discovering, developing, and commercializing small molecule drugs for the treatment of serious diseases, including human immunodeficiency virus infection, chronic hepatitis C virus (HCV) infection, cancer and bacterial infection. At Dec 31 2007, Co. concentrated most of its drug development resources on four drug candidates: telaprevir (VX-950) for the treatment of HCV infection, VX-702 for the treatment of rheumatoid arthritis and other inflammatory diseases, VX-770 for the treatment of cystic fibrosis and VX-883 for the treatment of bacterial infection. Co.'s pipeline also includes several drug candidates that are being developed by its collaborators.

Key Competitors

advertisement
Vertex Pharmaceuticals Inc. Company Info

Board of Directors

Dr. Charles A. Sanders

Chairman

Dr. Stuart J.M. Collinson Ph.D.

Ms. Eugene H. Cordes Ph.D.

Mr. Matthew W. Emmens

Mr. Eric K. Brandt

Dr. Roger W. Brimblecombe Ph.D.

Mr. Bruce I. Sachs

Dr. Joshua S. Boger Ph.D.

Ms. Elaine S. Ullian

Contact Information

130 Waverly Street

Cambridge, MA

http://www.vrtx.com

617 444-6100

NAICS Code

Pharmaceutical Preparation Manufacturing: 325412
advertisement